What is the P/E ratio of Jacobson Pharma Corporation 2024?
The Jacobson Pharma Corporation P/E ratio is 4.17.
The Quote Chart provides detailed and dynamic insights into the Jacobson Pharma Corporation stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.
The intraday feature provides real-time data, allowing investors to view the Jacobson Pharma Corporation stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.
View the total return of the Jacobson Pharma Corporation stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.
Utilize the comprehensive data presented in the Quote Chart to analyze Jacobson Pharma Corporation's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.
Date | Jacobson Pharma Corporation Price |
---|---|
9/4/2024 | 0.58 HKD |
9/3/2024 | 0.58 HKD |
9/2/2024 | 0.61 HKD |
8/30/2024 | 0.61 HKD |
8/29/2024 | 0.60 HKD |
8/28/2024 | 0.59 HKD |
8/27/2024 | 0.59 HKD |
8/26/2024 | 0.58 HKD |
8/23/2024 | 0.58 HKD |
8/22/2024 | 0.58 HKD |
8/21/2024 | 0.57 HKD |
8/20/2024 | 0.57 HKD |
8/19/2024 | 0.58 HKD |
8/16/2024 | 0.57 HKD |
8/15/2024 | 0.59 HKD |
8/14/2024 | 0.58 HKD |
8/13/2024 | 0.59 HKD |
8/12/2024 | 0.57 HKD |
8/9/2024 | 0.59 HKD |
8/8/2024 | 0.58 HKD |
3 years
5 years
10 years
25 Years
Max
Gain insights into Jacobson Pharma Corporation, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Jacobson Pharma Corporation from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Jacobson Pharma Corporation’s net earnings, an ultimate measure of its financial health and profitability.
Observe the yearly bars to understand the annual performance and growth of Jacobson Pharma Corporation. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
The expected values for the forthcoming years offer investors a glimpse into Jacobson Pharma Corporation’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Leveraging the comparison between Revenue and EBIT helps in assessing Jacobson Pharma Corporation’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Jacobson Pharma Corporation’s growth potential.
Date | Jacobson Pharma Corporation Revenue | Jacobson Pharma Corporation EBIT | Jacobson Pharma Corporation Net Income |
---|---|---|---|
2024 | 1.47 B HKD | 311.4 M HKD | 266.97 M HKD |
2023 | 1.27 B HKD | 269.27 M HKD | 251.04 M HKD |
2022 | 1.6 B HKD | 245.97 M HKD | 177.67 M HKD |
2021 | 1.45 B HKD | 164.33 M HKD | 173.71 M HKD |
2020 | 1.57 B HKD | 303.17 M HKD | 215.63 M HKD |
2019 | 1.48 B HKD | 339.07 M HKD | 250.56 M HKD |
2018 | 1.55 B HKD | 280.12 M HKD | 202.27 M HKD |
2017 | 1.26 B HKD | 225.79 M HKD | 179.33 M HKD |
2016 | 1.08 B HKD | 190.2 M HKD | 145.61 M HKD |
2015 | 947.59 M HKD | 137.72 M HKD | 101.9 M HKD |
2014 | 926.2 M HKD | 162.4 M HKD | 172.4 M HKD |
Revenue | EBIT | Net Income | |
---|---|---|---|
2014 | 926.2 M HKD | 162.4 M HKD | 172.4 M HKD |
2015 | 947.59 M HKD | 137.72 M HKD | 101.9 M HKD |
2016 | 1.08 B HKD | 190.2 M HKD | 145.61 M HKD |
2017 | 1.26 B HKD | 225.79 M HKD | 179.33 M HKD |
2018 | 1.55 B HKD | 280.12 M HKD | 202.27 M HKD |
2019 | 1.48 B HKD | 339.07 M HKD | 250.56 M HKD |
2020 | 1.57 B HKD | 303.17 M HKD | 215.63 M HKD |
2021 | 1.45 B HKD | 164.33 M HKD | 173.71 M HKD |
2022 | 1.6 B HKD | 245.97 M HKD | 177.67 M HKD |
2023 | 1.27 B HKD | 269.27 M HKD | 251.04 M HKD |
2024 | 1.47 B HKD | 311.4 M HKD | 266.97 M HKD |
Simple
Expanded
Income Statement
Balance Sheet
Cashflow
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
0.93 | 0.95 | 1.08 | 1.26 | 1.55 | 1.48 | 1.57 | 1.45 | 1.6 | 1.27 | 1.47 |
- | 2.27 | 14.36 | 15.88 | 23.35 | -4.52 | 6.29 | -8.02 | 10.38 | -20.56 | 15.79 |
45.79 | 40.55 | 44.97 | 44.30 | 39.86 | 45.60 | 43.86 | 38.82 | 38.87 | 42.46 | 42.26 |
424 | 384 | 487 | 556 | 617 | 674 | 689 | 561 | 620 | 538 | 620 |
162 | 137 | 190 | 225 | 280 | 339 | 303 | 164 | 245 | 269 | 311 |
17.49 | 14.47 | 17.54 | 17.93 | 18.09 | 22.94 | 19.29 | 11.35 | 15.36 | 21.23 | 21.20 |
172 | 101 | 145 | 179 | 202 | 250 | 215 | 173 | 177 | 251 | 266 |
- | -41.28 | 43.56 | 23.45 | 12.85 | 23.76 | -14.00 | -19.53 | 2.31 | 41.81 | 5.98 |
- | - | - | - | - | - | - | - | - | - | - |
- | - | - | - | - | - | - | - | - | - | - |
1.31 | 1.31 | 1.31 | 1.57 | 1.82 | 1.93 | 1.98 | 1.92 | 1.92 | 1.91 | 1.92 |
- | - | - | - | - | - | - | - | - | - | - |
The Jacobson Pharma Corporation Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.
The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.
EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.
Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.
Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.
Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.
Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Jacobson Pharma Corporation is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.
3 years
5 years
10 years
25 Years
Max
The gross margin, expressed as a percentage, delineates the gross profit made from the Jacobson Pharma Corporation's sales revenue. A higher gross margin percentage indicates that the Jacobson Pharma Corporation retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT margin represents the Jacobson Pharma Corporation's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
The revenue margin demonstrates the Jacobson Pharma Corporation's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Jacobson Pharma Corporation's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Jacobson Pharma Corporation. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Jacobson Pharma Corporation's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Jacobson Pharma Corporation Gross margin | Jacobson Pharma Corporation Profit margin | Jacobson Pharma Corporation EBIT margin | Jacobson Pharma Corporation Profit margin |
---|---|---|---|
2024 | 42.27 % | 21.22 % | 18.19 % |
2023 | 42.51 % | 21.24 % | 19.8 % |
2022 | 38.89 % | 15.42 % | 11.14 % |
2021 | 38.8 % | 11.36 % | 12.01 % |
2020 | 43.91 % | 19.29 % | 13.72 % |
2019 | 45.64 % | 22.94 % | 16.95 % |
2018 | 39.88 % | 18.09 % | 13.06 % |
2017 | 44.34 % | 17.98 % | 14.28 % |
2016 | 45 % | 17.55 % | 13.43 % |
2015 | 40.6 % | 14.53 % | 10.75 % |
2014 | 45.86 % | 17.53 % | 18.61 % |
Gross margin | EBIT margin | Profit margin | |
---|---|---|---|
2014 | 45.86 % | 17.53 % | 18.61 % |
2015 | 40.6 % | 14.53 % | 10.75 % |
2016 | 45 % | 17.55 % | 13.43 % |
2017 | 44.34 % | 17.98 % | 14.28 % |
2018 | 39.88 % | 18.09 % | 13.06 % |
2019 | 45.64 % | 22.94 % | 16.95 % |
2020 | 43.91 % | 19.29 % | 13.72 % |
2021 | 38.8 % | 11.36 % | 12.01 % |
2022 | 38.89 % | 15.42 % | 11.14 % |
2023 | 42.51 % | 21.24 % | 19.8 % |
2024 | 42.27 % | 21.22 % | 18.19 % |
3 years
5 years
10 years
25 Years
Max
Revenue per share represents the total revenue Jacobson Pharma Corporation earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT per share indicates Jacobson Pharma Corporation's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income per share, or earnings per share (EPS), reveals the portion of Jacobson Pharma Corporation’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Jacobson Pharma Corporation's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
Date | Jacobson Pharma Corporation Sales per Share | Jacobson Pharma Corporation EBIT per share | Jacobson Pharma Corporation Earnings per Share |
---|---|---|---|
2024 | 0.76 HKD | 0.16 HKD | 0.14 HKD |
2023 | 0.66 HKD | 0.14 HKD | 0.13 HKD |
2022 | 0.83 HKD | 0.13 HKD | 0.09 HKD |
2021 | 0.75 HKD | 0.09 HKD | 0.09 HKD |
2020 | 0.79 HKD | 0.15 HKD | 0.11 HKD |
2019 | 0.77 HKD | 0.18 HKD | 0.13 HKD |
2018 | 0.85 HKD | 0.15 HKD | 0.11 HKD |
2017 | 0.8 HKD | 0.14 HKD | 0.11 HKD |
2016 | 0.83 HKD | 0.14 HKD | 0.11 HKD |
2015 | 0.72 HKD | 0.1 HKD | 0.08 HKD |
2014 | 0.71 HKD | 0.12 HKD | 0.13 HKD |
Sales per Share | EBIT per share | Earnings per Share | |
---|---|---|---|
2014 | 0.71 HKD | 0.12 HKD | 0.13 HKD |
2015 | 0.72 HKD | 0.1 HKD | 0.08 HKD |
2016 | 0.83 HKD | 0.14 HKD | 0.11 HKD |
2017 | 0.8 HKD | 0.14 HKD | 0.11 HKD |
2018 | 0.85 HKD | 0.15 HKD | 0.11 HKD |
2019 | 0.77 HKD | 0.18 HKD | 0.13 HKD |
2020 | 0.79 HKD | 0.15 HKD | 0.11 HKD |
2021 | 0.75 HKD | 0.09 HKD | 0.09 HKD |
2022 | 0.83 HKD | 0.13 HKD | 0.09 HKD |
2023 | 0.66 HKD | 0.14 HKD | 0.13 HKD |
2024 | 0.76 HKD | 0.16 HKD | 0.14 HKD |
The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.
This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.
Example 2022
Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)
It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.
Example 2022
Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)
This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.
Example 2022
Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)
Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.
Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.
3 years
5 years
10 years
25 Years
Max
Revenue per share represents the total revenue Jacobson Pharma Corporation earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT per share indicates Jacobson Pharma Corporation's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income per share, or earnings per share (EPS), reveals the portion of Jacobson Pharma Corporation’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Jacobson Pharma Corporation's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
Number of stocks | |
---|---|
2014 | 1.31 B Aktien |
2015 | 1.31 B Aktien |
2016 | 1.31 B Aktien |
2017 | 1.57 B Aktien |
2018 | 1.82 B Aktien |
2019 | 1.93 B Aktien |
2020 | 1.98 B Aktien |
2021 | 1.92 B Aktien |
2022 | 1.92 B Aktien |
2023 | 1.91 B Aktien |
2024 | 1.92 B Aktien |
3 years
5 years
10 years
25 Years
Max
The dividend per year chart for Jacobson Pharma Corporation provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.
A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Jacobson Pharma Corporation’s potential for long-term investment and income generation through dividends.
Incorporate the dividend data in evaluating Jacobson Pharma Corporation's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.
Date | Jacobson Pharma Corporation Dividend |
---|---|
2024 | 0.03 HKD |
2023 | 0.07 HKD |
2022 | 0.05 HKD |
2021 | 0.03 HKD |
2020 | 0.03 HKD |
2019 | 0.05 HKD |
2018 | 0.04 HKD |
2017 | 0.03 HKD |
Dividend | Dividend (Estimate) | |
---|---|---|
2014 | 0 HKD | 0 HKD |
2015 | 0 HKD | 0 HKD |
2016 | 0 HKD | 0 HKD |
2017 | 0.03 HKD | 0 HKD |
2018 | 0.04 HKD | 0 HKD |
2019 | 0.05 HKD | 0 HKD |
2020 | 0.03 HKD | 0 HKD |
2021 | 0.03 HKD | 0 HKD |
2022 | 0.05 HKD | 0 HKD |
2023 | 0.07 HKD | 0 HKD |
2024 | 0.03 HKD | 0 HKD |
3 years
5 years
10 years
25 Years
Max
The yearly payout ratio for Jacobson Pharma Corporation represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.
A lower payout ratio for Jacobson Pharma Corporation could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.
Evaluate Jacobson Pharma Corporation's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.
Date | Jacobson Pharma Corporation Payout ratio |
---|---|
2024 | 42.9 % |
2023 | 39.82 % |
2022 | 59.09 % |
2021 | 29.78 % |
2020 | 30.58 % |
2019 | 39.33 % |
2018 | 39.49 % |
2017 | 27.22 % |
2016 | 39.82 % |
2015 | 39.82 % |
2014 | 39.82 % |
Payout ratio | |
---|---|
2014 | 39.82 % |
2015 | 39.82 % |
2016 | 39.82 % |
2017 | 27.22 % |
2018 | 39.49 % |
2019 | 39.33 % |
2020 | 30.58 % |
2021 | 29.78 % |
2022 | 59.09 % |
2023 | 39.82 % |
2024 | 42.9 % |
Date | EPS Estimate | EPS Actual | Quarterly report |
---|---|---|---|
3/31/2018 | 0.1 HKD | 0.07 HKD (-34.31 %) | 2018 Q4 |
3/31/2017 | 0.06 HKD | 0.08 HKD (32.89 %) | 2017 Q4 |
% | Name | Stocks | Change | Date |
---|---|---|---|---|
7.93 % | Longjin Investments Ltd. | 157,050,000 | 0 | 2/27/2024 |
42.96 % | Kingshill Development Ltd. | 850,684,000 | 0 | 4/15/2024 |
17.06 % | Sum (Kwong Yip Derek) | 337,854,000 | 0 | 4/15/2024 |
10.10 % | Yunnan Baiyao Group Co., Ltd. | 200,000,000 | 0 | 2/27/2024 |
1.99 % | Yim (Chun Leung) | 39,420,000 | 0 | 4/15/2024 |
0.39 % | Pun (Yue Wai) | 7,810,000 | 0 | 4/15/2024 |
0.24 % | Dimensional Fund Advisors, L.P. | 4,712,000 | 0 | 3/31/2024 |
0.04 % | Dimensional Fund Advisors, Ltd. | 694,000 | 0 | 1/31/2024 |
0.03 % | Lam (Kwing Tong) | 600,000 | 0 | 2/27/2024 |
0.03 % | California State Teachers Retirement System | 500,000 | 0 | 6/30/2023 |
The Jacobson Pharma Corporation P/E ratio is 4.17.
The Jacobson Pharma Corporation P/S ratio is 0.76.
The AlleAktien quality score for Jacobson Pharma Corporation is 5/10.
The Jacobson Pharma Corporation revenue is 1.47 B HKD.
The Jacobson Pharma Corporation profit is 266.97 M HKD.
No history available for Jacobson Pharma Corporation.
Jacobson Pharma Corporation pays a dividend of 0.05 HKD distributed over payouts per year.
The dividend cannot currently be calculated for Jacobson Pharma Corporation or the company does not pay out a dividend.
The ISIN of Jacobson Pharma Corporation is KYG677291067.
The ticker of Jacobson Pharma Corporation is 2633.HK.
Over the past 12 months, Jacobson Pharma Corporation paid a dividend of 0.03 HKD . This corresponds to a dividend yield of about 5.17 %. For the coming 12 months, Jacobson Pharma Corporation is expected to pay a dividend of 0.03 HKD.
The current dividend yield of Jacobson Pharma Corporation is 5.17 %.
Jacobson Pharma Corporation pays a quarterly dividend. This is distributed in the months of January, September, January, October.
Jacobson Pharma Corporation paid dividends every year for the past 8 years.
For the upcoming 12 months, dividends amounting to 0.03 HKD are expected. This corresponds to a dividend yield of 5.17 %.
Jacobson Pharma Corporation is assigned to the 'Health' sector.
To receive the latest dividend of Jacobson Pharma Corporation from 10/4/2024 amounting to 0.03 HKD, you needed to have the stock in your portfolio before the ex-date on 9/3/2024.
The last dividend was paid out on 10/4/2024.
In the year 2023, Jacobson Pharma Corporation distributed 0.073 HKD as dividends.
The dividends of Jacobson Pharma Corporation are distributed in HKD.
Jacobson Pharma Corporation Ticker | Jacobson Pharma Corporation FIGI |
---|---|
2633:HK | BBG00DRGW9B9 |
Our stock analysis for Jacobson Pharma Corporation Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Jacobson Pharma Corporation Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.